CClinicalTrials.gg
Active, not recruitingNCT05362370Updated May 29, 2026

Stryker PEEK Customized Implant: A Prospective Post Market Follow Up to Evaluate Safety, Performance and Effectiveness

An observational study in Cranioplasty, Craniofacial Abnormalities and Craniofacial Injuries, sponsored by Stryker Craniomaxillofacial. Active, not recruiting at 13 sites in 6 countries. Open to participants aged 42 Months and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Stryker Craniomaxillofacial · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
99
Ages
42 Months and older
Sex
All
01

Study summary

The purpose of this study is to confirm the safety, performance and effectiveness of Stryker's PEEK Customized Implants when used for the augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton. The study is designed as a prospective, multi-center trial with a long-term follow-up (up to 24-months) of study participants.

Read the detailed description

Stryker's PEEK Customized Implants are patient-specific implants based on CT-data of the individual patient and input of the surgeon. The implants are fabricated from Polyetheretherketone (PEEK) and intended to be used to fill bony voids in the cranial and craniofacial region (e.g. cranium, orbital rim, zygoma, and adjacent bone). This observational post-market clinical follow-up (PMCF) is designed to confirm the safety, performance and clinical benefit of Stryker's PEEK Customized Implants for the augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH). Infection of implants is one of the common risks associated with this type of surgery. This PMCF study will investigate infection rate as the primary safety endpoint. These data will be collected in a real world setting, where all treatment is per routine clinical practice. The study is designed as a prospective, multi-center trial at participating institutions in the United States and in Europe. Up to 110 study participants will be enrolled in this PMCF. Stryker's PEEK Customized Implants are intended to stay implanted permanently. Therefore, study participants will be followed for up to 24-months after implantation of the devices to allow evaluation of long-term safety and performance of the products.

02

Conditions studied

  • Cranioplasty
  • Craniofacial Abnormalities
  • Craniofacial Injuries
03

Who can participate

Ages eligible
42 Months and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with cranial and craniofacial defects requiring augmentation and/or restoration, e.g. following tumor resection, trauma, vascular conditions, or stroke requiring craniectomy, due to previously failed cranioplasty, or bone flap resorption.

Inclusion criteria

  1. Subject is eligible for a PEEK customized implant as per routine clinical practice.
  2. Subject is 12 years of age or older (Europe only).
  3. Subject is 3.5 years of age or older (USA only).
  4. Adult subjects able to give consent.
  5. Subjects under the age of 18 will have a legal representative or parents (France - both parents must sign) to provide informed consent.
  6. Subjects who are unable to give consent themselves but have a legally authorized representative that may consent on their behalf.

Exclusion criteria

Exclusion Criteria

  1. Subject has an active systemic or local infection.
  2. Subject has known allergy to plastic or polymers and/or known sensitivity to foreign bodies.
  3. Comprised bone due to poor blood supply, disease, infection or prior implantation, which would not allow adequate support or fixation of the implant.
  4. Mental or neuromuscular disorder which could create an unacceptable risk of implant instability or implant fixation failure, or complications in postoperative care.
  5. Knowingly pregnant or nursing women.
  6. Concomitant participation in other clinical trials related to cranioplasty.
  7. Subject who has an expected survival rate of less than 2 years, in the opinion of the investigator who takes consent.
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
99 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Participants will receive a Stryker PEEK Customized Implant

    Device: Stryker's PEEK Customized Implant

Interventions

  • DeviceStryker's PEEK Customized Implant

    The PEEK Customized Implants will be used in this patient cohort for augmentation and/or restoration of bony and/or soft tissue deformities in the cranial and craniofacial skeleton (orbital rim, zygoma, and adjacent bone); including but not limited to, the correction and prevention of persistent temporal hollowing (PTH).

05

What researchers measure

Primary outcomes

  1. Infection Rate

    Assessment of rate of infection associated with Stryker's PEEK Customized Implants.

    Time frame: Up to 24 months post-operative

Secondary outcomes

  1. Incidence of device related serious adverse events (SAEs)

    Incidence of device related SAEs up to 24 months post implantation

    Time frame: Up to 24 months post-operative

  2. Ability to place the Customized Implant during surgery leading to good aesthetic outcome

    Assessment of success of placement by the surgeon as determined by the ability to close the defect effectively, even with modification of implant

    Time frame: Up to 24 months post-operative

  3. Rate of implant failure

    Rate of implant failure leading to explantation

    Time frame: Up to 24 months post-operative

  4. Quality of life questionnaire

    Outcome of Short Form health survey-12 (SF-12) quality of life questionnaire

    Time frame: Up to 24 months post-operative

  5. Length of hospitalisation

    Time duration after surgery until hospital discharge

    Time frame: 1 month

  6. Persistent temporal hollowing

    Presence of persistent temporal hollowing after the procedure

    Time frame: Up to 24 months post-operative

  7. Neurological Assessment

    Glasgow Coma Scale

    Time frame: Up to 24 months post-operative

  8. Scale of brain injuries

    Glasgow Outcome Scale Extended

    Time frame: Up to 24 months post-operative

  9. Aesthetic assessment

    Aesthetic assessment score

    Time frame: Up to 24 months post-operative

06

Study locations

13 sites
  • University of Louisville 501 E. Broadway, Suite 210
    Louisville, Kentucky 40202, United States
  • Department of Neurological Surgery
    New Brunswick, New Jersey 07101-1709, United States
  • Department of Neurological Surgery, 710 West 168th Street, 4th Floor, New York Presbyterian Hospital
    New York, New York 10032, United States
  • Lewis Katz School of Medicine at Temple University, 3401 North Broad Street
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of South Carolina, Oral & Maxillofacial Surgery, 173 Ashley Avenue, Charleston, USA
    Charleston, South Carolina 29425, United States
  • Universitätsklinik für Neurochirurgie Auenbruggerplatz 29
    Graz, 8036, Austria
  • Pierre-Paul Riquet Hospital, Place du Docteur Baylac, Cedex 9
    Toulouse, Occitanie TSA 40031 - 31059, France
  • APHP - Hôpital Lariboisière Neurochirurgie 2 rue Ambroise Paré
    Paris, Paris France 75010, France
  • CHU Nantes - Hopital Guillaume et Rene Laënnec, Cedex 1
    Nantes, Pays de la Loire Region 44093, France
  • St. Barbara-Klinik Hamm GmbH Hamm Heessen und St. Josef-Krankenhaus Hamm-Bockum-Hövel Am Heessener Wald 1 | 1263
    Hamm, Hamm 59073, Germany
  • Klinik für Neurochirurgie Klinikum Dortmund Münsterstr. 240
    Dortmund, North Rhine-Westphalia 44145, Germany
  • Servicio de Neurocirugía Hospital Universitario La Paz.
    Madrid, Madrid 28046, Spain
  • Neurosurgery, Emergency and Major Trauma (NET) Research | Division of Medicine | Imperial College Healthcare NHS Trust
    London, London SW7 2AZ, United Kingdom
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT05362370
Lead sponsor
Stryker Craniomaxillofacial
Collaborators
Qmed Consulting A/S
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Feb 1, 2023
Primary completion
Nov 30, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion